Fairmount’s Big Buy During Viridian’s Fund‑Raising Wave Signals Strong Institutional Confidence in the Biotech’s Growth Prospects
Fairmount’s $17 buy of 1.18 M Viridian shares after the $117 M equity round signals strong confidence in the biotech’s TED pipeline and growth strategy.
3 minutes to read